Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants

Model scores of the 29,894 trials active now.

Model score 8% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 10% of the time (528 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-08-07. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: lungtherapysclerosisdiseasemultiple
  Phrases that lowered it: asthmavisitscreeningto evaluateevaluate the
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Sponsor's past termination rate: 10.3% (raises risk) · Sponsor's track record
• Sponsor's past trials: 901 (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 53.1% (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 5.1% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Has a data monitoring committee: No (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 68 (lowers risk) · Sponsor's track record
• Blinding: quadruple (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Number of arms: 4 (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Disease area, respiratory: Yes (raises risk) · Disease area
• Disease area, neurology: No (lowers risk) · Disease area
• Maximum age: 70 (raises risk) · Who can join
• Minimum age: 18 (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma NCT02528214 · started 2015 · scored riskier than 8% of active trials completed
• Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) NCT03186209 · started 2017 · scored riskier than 10% of active trials completed
• Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic Participants NCT02495168 · started 2017 · scored riskier than 6% of active trials completed
• A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma NCT03676413 · started 2018 · scored riskier than 6% of active trials completed
• Efficacy and Safety of CP006 Inhalation Powder in Participants With Asthma NCT07807007 · started 2025 · scored riskier than 7% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.